CEO Ron Cooper said the company’s focus is advancing its DDX platform, a proprietary non-viral gene therapy technology, with its lead program detalimogene being developed for non-muscle invasive ...

Executives from enGene (NASDAQ:ENGN) provided an update on the company’s detalimogene program in non-muscle invasive bladder ...

Prostate cancer is the most commonly diagnosed cancer in the UK. But screening is not universal, and charities are divided over whether it should be extended. What do those living with the disease ...

Despite the severe pain kidney stones can cause, doctors say there are few medicines designed specifically to prevent them - something Stanford researchers hope to change.